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INTRODUCTION 
INTRODUCTION 
 
               Snakes are fascinating part of nature. Their colour, movement 
and secret habits make them more mysterious. India is home to some of 
the most poisonous snakes in the world, most of which are found in rural 
areas. 
(1) 
Snake bites cause substantial mortality and morbidity in India. A 
large proportion of snake bites occur when people are working barefoot 
in the fields, or while walking at night or early morning through fields or 
along roads. (2) Superstitions, wrong practices, misconceptions (3,4) 
handicap doctors who care primary attention. 
(5)
. Of 3000 species of 
snakes known to world, in India, we have around 216 species, out of 
which 52 are known to be poisonous. (6)    Our venomous species belong 
to two major families: Elapidae, Viperidae. 
 
               Snake bite envenomation is a common problem in  this part of 
state.The clinical profile and outcome  depends on various factors. Large 
number of cases are admitted every day in Coimbatore Medical College 
Hospital. Our study is to  analyse  the epidemiology of snake bite 
envenomation cases in this part of state ,to study the clinical profile and 
various complications  of snake bite envenomation , to study the 
influence of the time interval  between the starting of  treatment with 
reference to  prognosis ,  to study the amount of ASV  that may be useful 
in treatment  and preventing morbidity and mortality. 
  
 
 
 
 
 
 
 
 
 
 
 
 
AIM OF THE STUDY 
 AIM OF THE  STUDY 
1.  To   study the epidemiology of snake bite envenomation cases in this 
part of state. 
2.  To study the clinical profile and various complications  of  snake bite 
envenomation. 
3.  To study the influence of the time interval  between the starting of  
treatment with reference to  prognosis. 
 4.   To study the amount of ASV  that may be useful in treatment   and 
preventing morbidity and mortality. 
5. To study the prognostic factors in snake bite envenomation.     
                            
 
 
 
 
 
 
                                           
  
  
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE   
 REVIEW OF LITERATURE 
 
            Snake bite poisoning is a preventable health hazard in tropics. 
Very extensive toxicological research is still going on, because of high 
incidence. It  accounts for 100-150 deaths per day in India and the annual 
deaths per year is around 30,000.(6) It is a cause for major preventable 
death. In India, the highest incidence are in Tamil Nadu, West Bengal, 
Maharashtra, U.P and Kerala
.(7) 
 
Snake bites happen when the farmers work in field bare footed, 
unintentionally in a handful of foliage, rolling over the snake while 
asleep, while working in other plantation and in snake handlers
.(8)
 Males 
are bitten more often than females
(9)
 with majority of bites being on the 
lower extremities.
(10) 
Majority of victim initially are treated by traditional 
snake bite healers. 
 
Death often occurs even before the patient reaches hospital.
(5) 
The 
use of protective foot wear, long trousers and lighting at night could 
reduce the incidence of snake bites. Effective rodent control could also 
help. 
(12)
 Poisonous snakes prevalent in India belong to 3 families. 
(13)
 
They are: 
1) Elapidae:  includes Cobras and Krait – Neurotoxic. Renal involvement 
is less common in victims bitten from members of this family. 
2) Viperidae: Russell viper and saw scale viper – Vasculotoxic. 
3) Sea snake: Myotoxic. 
Renal involvement has been associated with bites from last two families
. 
(14), (15) 
 
COBRAS: 
The two species of Cobras found in India 
(16)
 are common Cobra 
(NallaPambu) 
(17)
 and King Cobra (Raja Nagam, Karu Nagam). 
(17) 
The 
Cobra has hood which on dorsal side often bears a double or single 
spectacle mark. It is distributed throughout India. King cobra is black in 
colour and has hood but no mark on it. They are found in Himalayas, 
Bengal, Assam and Andaman Islands. 
(18) 
 
KRAIT:  
The two species of krait commonly found in India(16) are common 
krait  (Kattu Viriyan) 
(17)
 and banded krait (Pattai Kattu Viriyan).
 (17) 
The 
common Krait has steel blue or black with white bars on the back. It is 
distributed through out India. 
(18)
 Banded krait is jet black with yellow 
stripes on its back. They  are found in Bengal, Assam, Bihar, Orissa, 
Madhya Pradesh, Andhra Pradesh and Uttar Pradesh.
 (18) 
 
 
VIPER: 
The two species of viper that are commonly found in India 
(16)
 are 
Russell viper (Kannadi Viriyan)(17) and Saw scale viper (Surruttai 
Viriyan).
(17) 
Russell viper has a triangular head with V shaped mark 
pointing forwards. It has a white body with dark semilunar spots. It is 
seen in Maharashtra, Punjab, Rajasthan, Tamil Nadu and Andhra 
Pradesh. Saw scaled viper has many white lines on each flank of the 
back, with diamond shaped areas between the two lines. It has white mark 
resembling an arrow over the head. It is seen in hills and plains 
throughout India. 
(18 
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EPIDEMIOLOGICAL FEATURES OF SNAKE BITE 
 
 
Documented reports of epidemiological studies of snake bite in 
India are few. Although the exact number of persons inflicted by snake 
bite is not known, it is estimated that about 2,00,000 persons are annually 
bitten by snakes in the country and about 15,000 of these are fatal (26). In a 
study conducted in Tamilnadu, hospital records showed a mortality of 
11.6%. According to a study by Sawai in 1974, 71% of the victims are 
found in the age group of 11-50 yrs and 75% of the victims were males. 
A Safdarjung Hospital study showed 81.5% of victims to be field 
workers. 75% bite occurred outdoors; 88.6% of victims were from rural 
India(
27)
. Incidence of snake bite in India shows a seasonal variation. In 
North India 70-80% of bites are seen in the warmer months may to 
October 
(27)
. While a study conducted in Calicut Medical College, Kerala 
showed a maximum incidence of complications also during this 
period
.(28).
 Sawai’s study in 1974 showed 68% of snake bites occurred in 
the evening and night; 32% in the morning and afternoon. 72% of bites 
were on the lower limbs; 25% on the hand and arm; and 3% were on the 
trunk. 
 
GENERAL FACTS ABOUT SNAKES 
      Snakes are cold blooded animals without ears or tympanic membrane. 
They react to vibrations received through the surface on which they rest 
rather than air borne vibrations. Snakes do not have a distinct visual 
system and they do not readily associate stationary objects with danger. 
Their sense of smell is  important. Most land snakes feed on mice, rats 
and frogs. Kraits and Cobras are exceptional in being mainly snake 
eaters. No one knows the life span of snakes in the wild. Longevity of 
some Indian snakes kept in zoos and by individuals include, Indian 
python : 34 yrs; Banded Kraits:11yrs; Indian cobras 21yrs; saw scaled 
&Russel viper: 10 yrs; . The south Indian tribals who have based their 
living on snakes are called ‘Irulas’. 
 
SNAKE VENOM: 
 The venom is a modified salivary secretion. The normal function of 
snake venom is to immobilize the prey and assist in digestion. The toxic 
component of snake venom is classified into 4 broad categories namely 
enzymes, polypeptides, glycoproteins and compounds of low molecular 
weight. They can also be classified as protein (90-95%) and non protein 
(5-10%) compounds. 
(19)
 It also contains Clostridia, Anaerobes and Gram 
negative bacilli. Since they cause septicemia, treatment with Tetanus 
Toxoid, Tetanus Immunoglobulin and metronidazole, gram positive and 
gram negative antibiotics is warranted. 
 
 
Table 1: COMPOUNDS PRESENT IN SNAKE VENOM
(20) 
 
 
ENZYMES 
Phopholipase A2 (lecithinase), 5’ nucleotidase, 
Collagenase, L-amino acid oxidase, Proteinases, 
Hyaluronidase, Acetylcholine esterase, Phospholipase B, 
Endopeptidase, Kininogenase, Factor X, Prothrombin 
activating enzyme. 
 
NON ENZYME 
POLYPEPTIDE 
 
(a)Polysynaptic  neurotoxin (α bungarotoxin and 
cobrotoxin),(b) Presynaptic  neurotoxin (β 
bungarotoxin, crotoxin, and taipoxin) ,cardiotoxin, 
crotamine. 
 
PEPTIDES 
 
Pyroglutamyl peptide 
 
NUCLEOSIDES 
 
Adenosine, Guanosine, Inosine 
 
LIPIDS 
 
Phospholipids, Cholesterol 
 
AMINES 
 
Histamine, Serotonin, Spermin 
 
METALS Copper, Zinc, Sodium, Magnesium 
 
 
 
 
 
  
VARIOUS SNAKES, THEIR FATAL DOSE, QUANTITY OF 
VENOM INJECTED, AND TIME TO FATALITY 
(21,22,29) 
 
 
 
SNAKE 
FATAL DOSE 
FOR HUMANS 
AVERAGE 
DELIVERED 
DOSE PER BITE 
AVERAGE 
FATAL PERIOD 
 
 
Indian cobra 
 
 
12mg 
 
 
0 .2g 
 
 
8h 
 
 
Common 
krait 
 
 
6mg 
 
 
0.22g 
 
 
18h 
 
 
Russels  viper 
 
 
15mg 
 
 
0.15g 
 
 
3days 
 
 
Sawscaled 
viper 
 
 
8mg 
 
 
0.13g 
 
 
41 days 
  
    The clinical presentation of a snake bite victim varies with the age and 
size of the patient, the species of snake, the number and location of the 
bites, the quantity and toxicity of the venom. Factors not contributing to 
outcome are size of the snake and time of bite (day/night). 
(8) 
 
  
ENZYMES   
(25,26,29) 
 
Arginine Esterase: 
 
This enzyme is produced by snakes belonging to Crotalidae and 
Viperidae. 
This enzyme has action similar to thrombin thereby causes coagulation 
and releases  bradykinin. 
 
Phospholipase A: 
 
It has a direct lytic effect, hemolytic effect and  causes hydrolysis of 
phospholipase of RBC membrane, thereby causing sudden fall in BP. 
(13) 
 
Cholinesterase: 
 
It is an important enzyme of Cobra. It hydrolyses  Acetyl choline into 
cholic acid and acetic acid. It has action similar to d-Tubocurarine and its 
effect is reversed by neostigmine. 
 
Acetyl Choline – Cobra – Crotalidae: 
 
It has direct action on heart and neuro muscular junction. 
 
 
Proteinase : 
 
Markedly present in Viper, Crotalidae. It causes tissue changes and 
destruction. 
  
Coagulant Effect: 
 
S  I   NO ENZYMES ACTIONS 
 
1 
 
Acetylcholine Esterase 
Catalysis and hydrolysis of acetylcholine 
 
2 
 
Arginine ester hydrolase 
Bradykinin release,interference with 
clotting 
3 Hyaluronidase  A 
(59) 
Reduction of collagen viscosity 
4 Phospholipase  A Uncoupling of oxidative phosphorylation 
5 Phospholipase B Hydrolysis of lysophosphatides 
 
6 
 
Phosphodiesterase Inhibition of  DNA,RNA arabinose 
derivatives 
7 5’ nucleotidase Specific Hydrolysis of PO4 Mono esterase  
which links with 5’position of DNA, RNA 
8 L- amino acid oxidase Catalysis  of amino acid 
9 Thrombin like enzymes Depression of  fibrinogen level 
10 Proteolytic enzymes  Tissue destruction and bleeding 
11 Collagenase  Collagen digestion 
 
 
 
 
 
 
 
 
 
Coagulant effect: 
 
It has anti coagulant effect due to proteolytic disintegration of Fibrinogen. 
 
It had coagulant effect by converting Prothrombin into Thrombin. 
 
 
Non Enzymatic Components: 
 
Haemorrhagins (HR-I, HR-II) – has direct action on endothelium with 
procoagulant and anticoagulant effects. It causes rapid haemorrhage, 
haemorrhages into visceral organs, vasoconstriction followed by 
vasodilatation of microvessels, haemorrhages into capillary bed and 
endothelial destruction
.(59) 
 
CLINICAL FEATURES 
 
The clinical features of snake bite can be considered under the following 
three headings:- 
1. Local effects. 
2. Systemic effects 
3.Complications. 
 
1. Local effects: 
 The limb bitten by the snake shows increased vascular permeability 
leading to swelling & bruising. Factors responsible include proteases, 
phospholipases, hyaluronidase and endogenous autocoids released by the 
snake venom like histamine and kinin. Venoms of some vipers cause a 
diffuse increase in vascular permeability causing pulmonary edema
.(30).
 
Local tissue necrosis occurs as a result of the direct action of myotoxic 
and cytotoxic factors, ischaemia due to thrombosis, external compression 
by tight tourniquets or swollen muscles
(30)
. Regional tender lymphadenitis 
is an important clinical sign, occurring early, and is toxin mediated. Local 
swelling is a valuable sign of viper bite to the extent that its absence 
excludes viper bite . Local swelling occurs rarely with the Asian cobra 
bite, but is not seen with Krait or sea – snake bites (31). 
 
2. Systemic features 
Fear and emotional reactions : Whether the snake is poisonous or non 
poisonous, fright is a common symptom. Patient may appear 
semiconscious with cold, clammy skin, feeble pulse and rapid shallow 
breathing
.(31) 
 
Bleeding and clotting disturbances: These are commonly seen after viper 
bites. This is due to procoagulant activity leading to consumption 
coagulopathy, anticoagulant activity inhibiting coagulation factors or due 
to thromobocytopenia
.(30).
 In the absence of trauma these generally donot 
causes spontaneous bleeding. If it occurs it is usually attributed to direct 
actions of haemorrhagic toxins
.(30).
 Commonest haemorrhagic 
manifestation seen in a study done by virmani and dutt in Jammu was 
haematuria ,while for Reid it was hemoptysis 
(32,33).
 Other common types 
of bleeding include haemetemesis and bleeding from gums, injection 
sites, and nose 
(32) .
 Discoid ecchymoses have been noted by Reid in his 
studies 
(33).
 A few Australian land snakes can cause haemolysis
.(30)
 
Neurological disturbances: Neurotoxic polypeptides and phospholipases 
of snake venom cause paralysis by blocking transmission at 
neuromuscular junctions ( post synaptic for krait and cobra, responds to 
neostigmine). 
(30)
,. This is characteristic of kraits, cobras and coral snakes. 
The early features would be prominent forehead wrinkles, then ptosis, 
external ophthalmoplegia and finally paralysis of bulbar muscle causing 
respiratory paralysis 
(30).
 Some patients bitten by elapids or vipers are in a 
physiologically drowsy state in the absence of respiratory or circulatory 
failure probably due to release and binding of endogenous opiates
.(30) 
Rhabdomyolysis : Generalised rhabdomyolysis with release of 
myoglobulin, muscle enzymes and potassium causes respiratory failure, 
hyperkalemia and occasionally renal failure (mainly seen in seasnakes). 
(30). 
3. Complications 
(i) Hypotension/shock: 
The cause of shock following snake bite include 
• Pain shock due to vasovagal mechanisms. 
• Vasodilating autocoids and oligopeptides in viper venom inhibit the 
kininase enzyme leading to vasodilatation and shock 
• Life – threatening anaphylactic reactions in previously sensitised 
individuals within minutes of being bitten. 
• Hypovolemia from loss of blood and plasma into swollen limb or 
massive gastro intestinal hemorrhage. 
• Direct myocardial action of toxin can contribute to hypotension  
( cardiogenic shock). 
• Pulmonary edema due to multiple effects (myocardial failure, increased 
permeability of pulmonary vessels) also contributes to shock. 
ii. Renal Failure: 
Ischemia (due to hypotension and DIC), nephrotoxic effect of venom, 
pigment nephropathy associated with rhabdomyolysis and intravascular 
haemolysis contribute to the development of acute tubular necrosis, 
bilateral cortical necrosis, and renal failure commonly seen with Russell 
viper.(34) It is the commonest cause of mortality in viper bite.(27) 
iii. Gangrene/necrosis: 
It is reported to be of high incidence in the United States of America and 
Japan following snake bite, but is rare in India.(27) 
 
  
PRINCIPAL FEATURES OF ENVENOMATION BY DIFFERENT 
FAMILIES OF SNAKES 
 
• Elapidae (krait / cobra) - principal manifestation is neurotoxicity. Local 
blisters and necrosis can occur. Australian Elapides cause bleeding 
manifestation.(30) 
• Viperidae ( Russell viper / Saw scaled viper) - local swelling, cellulitis, 
regional lymphadenitis and bleeding manifestations.
(30) 
• Hyperphiidae (sea snake) – Rhabdomyolysis .(30) 
• Colubridae : Bleeding manifestation and renal failure.
(30) 
 
INVESTIGATIONS IN A CASE OF SNAKE BITE 
1. Clotting Time: Incoagulable blood is a cardinal sign of systemic 
envenomation by majority of vipers. For clinical purposes a simple all or 
nothing test of blood coagulablity is adequate
(30)
. A few milliliters of 
blood taken by venepuncture are placed in a clean dry test tube
(30)
. More 
sensitive tests like prothrombin time and Fibrin degradation products are 
not used routinely and are indicated only in special situations.(30) Though 
snake bite is associated with thrombocytopenia, platelet count is not 
routinely needed until patient develops bleeding. 
 
2. Blood Urea , Serum Creatinine and Electrolytes are indicated to detect 
development of Renal failure
.(30) 
3.Urine Examination for red blood cells
.(30). 
4.White Blood cell count – Leucocytosis above 20,000 indicates severe 
envenomation 
5.Packed cell volume is done if patient develops bleeding. 
6.Additional Investigations: Done only in specific conditions. 
• Rhabdomyolysis (Sea Snake) – Rise in myoglobulin and creatine 
phosphokinase. 
• Renal failure – PH, PCo2, Bicarbonate estimation,Urine Sodium 
• Shock (Cardiotoxin) – Electrocardiogram. 
• Pulmonary Edema – Chest X-ray. 
 
IMMUNO DIAGNOSIS 
 Enzyme linked immunosorbent assay is a very important tool for 
studying both the epidemiological and clinical effects of snake bite in 
humans. In places where specific anti snake venom is available against 
each species, if the snake is not brought along with the victim for 
identification, immuno detection of specific snake venom antigen in body 
fluids of the patient will help in management
 12
 . It has been proved by 
ELISA that effects of envenomation depend upon hours ( i.e, Blood 
venom level X Time elapsed between bite and institution of treatment) 
rather than blood level of venom
.(35).
 Immunodiagnosis kits are unlikely to 
be of practical help unless their present cost is substantially reduced and 
speed of diagnosis is increased 
(36).
 Studies in Liverpool are in progress to 
increase the rapidity of assay to provide specific diagnosis within 10 
minutes of sampling 
(34)
.. ELISA by detection of snake venom antibody 
can be used for retrospective diagnosis of envenoming in epidemiological 
studies
(36) 
 
GRADING 
 Grading of the effects of viper bite has been done by different 
authors in varying patterns. The grading used by Reid in his study 
included both local and systemic effects in grading bites as those with nil, 
mild, moderate and severe envenomation
(32)
. In an Indian study this 
grading system was found to be complex and not very useful. 
 
A much simpler manner of grading would be:- 
Nil  No local cellulitis \ lymphadenitis ; CT normal 
Grade I  local cellulitis + regional adenitis; CT normal 
Grade II   CT prolonged +/- local signs 
Grade III  CT prolonged + systemic features like bleeding 
and shock
(37)
. 
 
 
  
MANAGEMENT 
General Measures: 
• Reassure the victim  
• Immobilize the bitten limb using a splint or sling 
• Cauterization, incision and drainage, amputation, usage of venom 
pumps, instillation of chemical compounds and electric shock locally are 
all to be avoided as these will cause uncontrolled bleeding from the site 
and damage of nerves and vessels, leading to necrosis.(30) 
• Use of tourniquets are controversial, dangers of their application 
include ischemia and gangrene, damage to peripheral nerves and 
increased local effect of venom. But in case of cobra or sea snake if 
medical therapy is likely to be delayed a firm crepe bandage can be 
applied. 
• Inj. Tetanus toxoid should be given. 
 
Specific therapy: 
ANTISNAKE VENOM THERAPY 
INDICATIONS: 
 Distinction of poisonous from non-poisonous snake is often 
difficult, and is not usually important for the clinician. It is known that 
about 15 drops of viper venom can be fatal to an adult and 3 drops of 
cobra venom could be lethal, and that one drop of sea snake could kill 5 
men. Fortunately snake bite is a defensive reaction which rarely results in 
much venom being injected. Following poisonous snake bite more than 
half of victims will have minimal or no poisoning. Hence poisonous 
snake bite is not synonymous with snake bite poisoning. So even though 
the snake is identified as poisonous, or there are bite marks, treatment 
should be given only if there are signs of envenomation. Antisnake 
venom itself can be fatal and it is a costly drug with limited supply
.(31) 
 
CLINICAL INDICATIONS 
- Hemostatic abnormalities 
- Neurotoxicity 
- Generalized rhabdomyolysis 
- Definite evidence of local envenomation. 
 
CONTRAINDICATIONS: 
There is no definite contraindication as Anti snake venom is the only 
specific therapy for snake bite. Atopic patients and those who had 
reaction to equine antiserum on previous occasions have an increased risk 
of developing severe antivenom reactions. It can be ameliorated by pre-
treatment with adrenaline, anti-histamine and corticosteroid.
(30) 
 
 
 
TYPES OF ANTI SNAKE VENOM: 
 Mono – specific forms are more effective and less likely to cause 
reactions than polyspecific antivenom. In most developing countries only 
a single polyspecific antivenom is available 
(36)
. In India ASV is produced 
by Haffkin Institute, Bombay, and Central Research Institute, Kasauli. It 
is produced by hyperimmunizing horses against the common four 
poisionous snake (Cobra, Krait, Russell’s and Saw scaled viper). 
(38) 
 
DOSE OF ANTI- VENOM: 
 The dose schedule for polyvalent and monovalent antisnake venom 
varies. We know the lethal dose of Cobra is 0.12g, Krait – 0.06g, Russell 
viper – 0.15g, Echis carinatus- 0.08g. 
 
 Poly valent anti- snake venom 1 ml neutratilses 0.6mg of cobra 
venom, 0.45mg of Krait, 0.6mg Russell viper and 0.45mg of Saw Scaled 
viper venom. Based on this if the poisonous snake is known , dose of anti 
snake venom can be estimated theoretically. But practically it is not 
applicable as amount of venom injected in each patient and by each bite 
varies. And in vitro studies do not correlate with in vivo results. Based on 
the results of a number of studies the dose of anti snake venom 
conventionally recommended as initial dose if snake is known is  
 
 
 
 Common krait – 100ml of Haffkine polyspecific antivenom. 
 Russell viper -100ml  
 Indian Cobra -100ml  and  
 Echis Carinatus -100ml(30).  
 
 If the snake is not known the recommended amount of anti snake 
venom given based on clinical signs is 50ml, 100ml, and 150ml for 
grades I to III. For patients presenting with neurotoxic features initial 
dose of ASV given is 100ml.
(37) 
 
 The apparent serum half-life of antisnake venom in envenomated 
patients ranges from 26 to 95 hours depending on how they are 
prepared
(30)
 .Though it clears the venom from the circulation 
immediately, the clinical effect on clotting restoration occurs usually after 
four hours. Thus if dose has been adequate clotting time should be normal 
by 6 hrs
(30,39)
. Neurotoxic signs improve within 30 mins but may take 
several hours. A second dose is given if neurological features persist for 
more than 30 minutes. Dose of ASV is the same for adults and 
children
.(30) 
 
 There is controversy about how long after envenomation anti – 
venom therapy is still effective. Carrison et al claim that it is most useful 
if given within 4hrs, less if delayed for 8 hrs, and doubtful if given after 
24hrs
 17
 .However, Dwivedi et al have reported therapy with anti snake 
venom to be beneficial even after  8 days and states that there is no fixed 
time limit
.(40) 
 
MODE OF ADMINISTRATION: 
 Local Injection: If it were possible to inject anti-venom locally at 
the site of bite within a few minutes, necrosis might well be prevented. 
But in practice this is virtually never possible and therefore is not 
advocated
.(31) 
  
 Intravenous injection: It is the most effective route. An infusion 
of anti-snake venom mixed with isotonic fluid is given in 1:3 dilution. It 
is given over 30-60 minutes, initially starting with 10-15 dps/mt and then 
increasing the dose 
(30).
 ASV can also be given direct intravenous bolus. It 
was found there is no difference in reaction between the two methods.(41) 
 
ANTIVENOM REACTIONS AND TESTDOSE 
Anti snake venom therapy is complicated by 3 types of reaction.  
1. Early (Anaphylactic), 2. Pyrogenic, 3. Late Serum sickness type 
reaction. Early anaphylactic reaction was initially thought to be IgE 
mediated. However, in most there is no prior exposure to serum. Skin test 
dose reactions do not correlate with the incidence of reactions occurring 
during ASV administration.
(30,41)
 Complement activation is also 
implicated, but not proved.
19
 Clinical features include itching, utricaria, 
fever, tachycardia, palpitations, nausea, and vomiting. Early reactions are 
managed by 0.5ml of 0.1% adrenaline sub cutaneous and 
chlorpherniramine maleate 10mgIV.
4
. Pyrogenic reactions results from 
contamination of anti- snake venom with endotoxin like compounds. 
High fever occurs which is treated with paracetomol. Late serum sickness 
reaction develops 5-24 days later,characterized by fever, itching, 
urticaria, arthralgia and lymphadenopathy, and is treated with 
chlorpheneramine 2mg four times daily or prednisolone 5 mg four times 
daily for 5 days
.(30).
The role of the intra dermal test with 0.2ml of ASV, 
though widely followed, is controversial. According to some authors, this 
test only delays the onset of definite therapy and has no role in the 
prediction of early or late Anti- snake venom reactions.
(30,41) 
 
Other supportive measures 
• Neurotoxic effects – Artificial Ventilation. 
Intravenous neostigmine 0.5mg given at half hourly interval 
for five injections. This is followed by same dose at increasing intervals 
of 2 to 12 hours according to neurological recovery. Each dose of 
neostigmine is preceeded by 0.6g atropine 
6 
. Shock- Plasma Expanders,  
Dopamine infusion, Steriods are used.
(30) 
 
•  Renal Failure – During initial oliguric phase (less than 
400ml/24hrs)dopamine infusion at the rate of 2.5 microgm/kg/minute 
or diuretics are used. In established renal failure, dialysis is 
indicated.
(30). 
•  Local infection: Intra compartmental syndrome – broad spectrum 
antibiotics are used. Blisters are best left undisturbed. Slough should 
be excised. Swelling of muscles within tight fascial compartments 
may raise the tissue pressure leading to impaired perfusion and 
ischemia. In these circumstances fasciotomy is indicated. It should be 
done only after blood coagulopathy has been treated. 
 
•  Steroids are advocated in both patients presenting with bleeding 
tendencies with neurological manifestations (Hydrocortisone 50 to 
100mg I.V 8th hrly). However, its use remains controversial .
(42) 
 
•  Heparin : Some studies show that if heparin 10,000 units is given 
intra venously stat followed by 5000 units 8th hrly IV and continued 
for 48 hrs it is useful in the prevention of DIC.21 Yet, other studies 
have shown it to be ineffective and worsening  bleeding
.(36). 
•  Fibrinogen infusions are not helpful
.(36) 
•  Blood Transfusion: Helps in viper bite shock secondary to bleeding 
and also helps in the management if specific antivenom is not 
available. 
  
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
  
MATERIALS AND METHODS 
 
Study type :  Descriptive study 
Population :  Patients with definite history of snake bite envenomation 
Setting :    Intensive medical care unit  Coimbatore medical college 
Duration:  September 2009  to  May  2010 
Inclusion   criteria : 
      Patient admitted in intensive care unit with definite history of snake 
bite or with signs of envenomation and not having any of the exclusion 
criteria 
Exclusion   criteria: 
       Patients admitted with unknown bite, or with history of  bite by non 
poisonous snakes or with no signs of envenomation. 
Methodology: 
 200 patients with definite history of snake bites or with definite 
features of envenomation as evidenced by cellulitis, bleeding 
manifestation, neurotoxicity or prolonged clotting time  enroll for study.  
  
    History included regarding application  of tourniquet  ,type of 
snake, time interval between bite and treatment  in previously  treated 
hospital and regarding native treatment . History  elicitation also  
regarding various symptomatology. Detailed clinical examination of the 
patient will be done. 
CLINICAL EXAMINATION 
LOCAL EXAMINATION 
           Site of snake bite   for the  presence of cellulitis   presence of ,fang 
marks, bleeding  from the site of bite, local necrosis and gangrene.  
 
GENERAL EXAMINATION 
          Pulse ,blood pressure, respiratory rate  will be noted and will look 
for haemorrhage , ecchymosis, bleeding  from puncture site, local lymph 
node enlargement, and   periorbital   oedema .Also  ptosis and extra 
ocular movements are examined for.Examination of the cardiovascular 
system,respiratory system,abdomen and  central nervous system will be 
followed. 
 
  
Lab investigation include 
1 Coagulation profile 
     Clotting time 
     Bleeding time 
     Haemoglobin 
     Total count 
     Differential count 
     Prothrombin time 
     Activated  partial thromboplastin time 
     Platelet count 
2 Liver function test 
    Serum bilirubin 
    SGOT 
    SGPT 
    Alkaline phosphatase 
   Total protein 
    Albumin 
   Globulin 
3 Serum  cholesterol 
4  Serum  uric acid 
5 Serum  calcium   
6 Renal parameters 
   Blood urea 
   Serum creatinine 
   Urine analysis 
       Albumin 
       Sugar 
       Red blood cell   count 
       White blood cell count 
       Deposits 
7 ECG 
 The  patient will be followed up in the ward  until discharge  
and  details regarding the complications developed  will be noted. 
  
ROUTINE TREATMENT GIVEN IN OUR HOSPITAL 
1.Tetanus toxoid  0.5ml  IM on admission. 
2. If signs of envenomation present polyvalent antisnakevenom is given 
3. Antibiotics - Penicillin, Metronidazole given parenterally ,dose 
according to body weight .Higher antibiotics like Ciprofloxacin 
,Cefotaxime when patient become febrile or develop septicemia. 
4.parameters like clotting time,worsening of renal failure,watched and if 
no improvement occurs ASV repeated as 50-100 ml each time until 
parameters are normalize. 
5. Urinary output is monitored and renal parameters watched regularly 
.Fluid and electrolyte balance maintained. Peritoneal dialysis, mostly 
and hemodialysis rarely done when required based on the indication. 
6. Injection heparin not used. 
7.Blood transfusion and dopamine administered when patients are in 
shock. 
8. Anti inflammatory drugs and wound care given accordingly. 
9. ASV allergy is treated with injection AVIL and intravenous 
Dexamethasone 0.8mg and injection Adrenaline. Dosage repeated if 
no significant improvement takes place .ASV drip restarted slowly 
and carefully and reaction watched. 
 ASV  available in Coimbatore medical college hospital is 
polyvalent .Each 1 ml neutralizes, 
• 0.6mg of dried cobra venom 
• 0.45 mg  of dried krait venom 
• 0.6mg   of Russel viper dried venom 
• 0.45 mg of dried saw scaled viper venom 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS AND ANALYSIS 
  
 Gender 
No of males  
No of females 
 
 
 
 
                                                          
 
RESULTS OF THE STUDY 
Total   no of patients -200 
No of Cases Percentage
144 72%
56 28%
 
 
 
 
 
AGE    DISTRIBUTION 
Age Group No. of Cases Percentage 
11-20 30 19.5% 
21-30 77 38.5% 
31-40 37 19% 
41-50 21 10.5% 
51-60 18 9% 
>60 7 3.5% 
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Type of snakes No of patients Percentage 
Viper 74 37% 
Cobra 22 11% 
Krait 15 7.5% 
Unidentified 89 44.5% 
37%
11%
8%
45%
viper cobra
krait unidentif ied
AREA DISTRIBUTION
AREA 
RURAL 
SEMI URBAN 
URBAN 
 
 
 
NO OF CASES PERCENTAGE
165 82.5%
26 13%
9 4.5%
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Period No of cases Percentage 
Sep-October 46 23% 
Nov –Dec 42 21% 
Jan-Feb 41 20.5% 
March-April 67 33.5% 
6
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SITE OF BITE 
 
    
 
 
  
SITE OF BITE NO OF PATIENTS PERCENTAGE 
Lower limb 128 64% 
Upper limb 67 33.5% 
Trunk 4 2% 
Face 1 0.5% 
CLINICAL PROFILE  OF SNAKE BITE ENVENOMATION
Manifestation
Pain and swelling
Oozing  from  site
Haematuria 
Oliguria 
Haematemesis 
Malena 
Epistaxis 
Drooping of eyelid
Respiratory paralysis
 
 
 No of cases Percentage
 152 
 62 
35 
76 
11 
21 
9 
 43 
 14 
 
 
76% 
31% 
17.5% 
38% 
5.5% 
10.5% 
4.5% 
21.5% 
7% 
 
TIME BETWEEN  BITE AND ASV ADMINISTRATION
Bite to needle time
<6hrs 
7-12hrs 
>12hrs 
 
 
. 
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
N
O
 O
F
 C
A
S
E
S
 (
%
)
 No .of cases Percentage
124 62%
59 29.5%
17 8.5%
<6hrs 7-12hrs >12hrs
BITE TO NEEDLE TIME
 
 
 
 
 
 
                              TOTAL NO OF ASV GIVEN                                           
TOTAL  VIALS OF ASV 
GIVEN 
NO OF CASES PERCENTAGE 
5-10  82 41% 
11-20 81 40.5% 
21-30 36 18% 
> 30 1 0.5% 
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                                              NUMBER OF DIALYSIS  
NO.OF DIALYSIS NO.OF CASES 
ONE 15 
TWO 9 
THREE 4 
FOUR 3 
 
 
 
 
 
ONE TWO THREE FOUR
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DATA OF EXPIRED PATEINTS 
 1 2 3 4 5 6 7 8 9 
Sex M M F M F M M M M 
Age 27 19 37 29 31 57 54  23 
Time delay in 
hospitalization(
hrs) 
5 5 16 24 12 6 24 16 6 
No.of vials of 
ASV received 
before 
admission  
5 3 10 0 5 3 6 5 4 
Total asv given 30 25 30 25 30 23 31 27 24 
hypotension + _ + + + + + _ + 
Subconjunctiva
l hemorrhage 
+ + _ + _ + _ + + 
ptosis _ _ + _ _ _ + _ _ 
Day of death 
after snake bite 
7 6 5 5 7 9 3 8 9 
 
 
BITE TO NEEDLE TIME AND   MORTALITY 
 
 
 
 
 
 
 
 OC TBAB (Hr) 
OC  Pearson Correlation  
 Sig. (2-tailed)  
 N  
1 
 
200 
 .723** 
 .000 
 200 
TBAB (Hr)  Pearson Correlation  
 Sig. (2-tailed)  
 N  
 .723** 
 .000 
 200 
1 
 
200 
**. Correlation is significant at the 0.01 level (2-tailed)  
The coefficient of  correlation, between outcome and time between ASV 
administration  and snake  bite is 0.723.means that earlier the arrival 
better the prognosis . 
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OUTCOME 
 
 
 
 
From the above table  chi square value of 49.575 for the association 
between subconjunctival haemorrhage and the poor outcome is highly 
significant. (p <.005). 
ANURIA AND OUTCOME 
 
From the above table chisquare value 33.45 for the association between 
anuria and poor outcome is highly significant.(p<.001). 
 
Crosstab
167 2 169
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DISCUSSION 
DISCUSSION 
 It is noted that  only 35% snake bite cases seek medical attention. 
Even in this there is higher incidence of male population. This may be 
either due to real increase in incidence of snake bite in males or due to 
female patients seeking native treatment or attending local hospitals due 
to neglect or indifference. The age distribution pattern shows more young 
people are the victims  (144 of them from 11-40 years). Tourniquet 
application rate is 30% in our study. 
            Majority of  patients are  from rural area (62.5%) and from urban 
area contribute about ( 4.5%). 
 Though most of our patients (62%) sought medical attention within 
6 hours after a snake bite, which is quite encouraging, administration of 
inadequate dosage of ASV  (4 of our 10 patients expired due to snake bite 
envenomation. They had received 5 vials or less of ASV outside our 
hospital and didn’t  have  the advantage of  early admission.) 
 This emphasizes the statement of Dr .David et al about the  
efficacy of early administration of ADEQUATE  Antisnake venom in 
snake bite envenomation. 
 We have used the photos of common snakes in our area which 
helped identification of snake  very easy for the patient and attenders, 
inspite of that  about 89  of the 200 snakes were un identified ,either 
because of nocturnal bite or patient was panicky to identify. So it tells us 
that using monovalent antisnake venom in our community will take a few 
more years  to get recognized.This also denied us of  knowing the 
common snakes of  this region and snakes producing both haematological 
and neurotoxicity which might be of important for therapy. Since 151 
patient had haematological toxicity alone ,viperidae may be common 
species here. 
 Our study shows a higher incidence of haematuria among patients 
with haematological manifestations where a study by Banerjee et al at 
Safdarjang hospital also supports the same. 
 In our study we noticed that 21 of our patient with haematological 
toxicity did not have cellulitis.  17 of them were admitted within    6  
hours after bite. This may be due to delayed systemic absorption   of 
venom, less local effect of venom ,or early neutralization of venom by 
ASV (Jacob et al). 
Another factor observed was 21 patients among 151 haematological 
toxicity cases ,had an initial normal clotting time on admission and which 
increased later after few hours.This may be explained by 
(1)
 the efficacy 
of tourniquet .(15 out of 21 patient had applied tourniquet and release of 
tourniquet might have caused systemic toxicity.
(2) 
Slower absorption of 
venom into circulation due to the large molecular weight haemotoxic 
substances. This fact necessitates  frequent estimation of clotting time if 
normal initially. 
In our  study 36 patients had renal impairement.clinically , biochemically 
or both. 7 out of them managed conservatively.29 patients underwent 
dialysis.  
In our study septicemia developed in 14 patients and  8 patients  only 
survived. 
In our study renal failure and septicemia were the common cause of 
death.  
In our study 43 (21.5%) developed drooping of eye lids .14 (7%)  patients 
developed respiratory paralysis .Out of 14 patients supported with 
mechanical ventilator  only two patient died. 
Jacob et al reports that only 2% of their patient required blood transfusion 
in our  study 12% patient required blood transfusion. 
It is difficult to fix the ASV requirements on admission and it has to be 
given as per the individuals response to prior ASV and assessed with 
clotting time and other parameters. With adequate ASV ,the clotting time 
normalize in  6 hrs. 
In our study 82 patients received 5-10 vials of ASV  and 81 received  11-
20 vials and 36 patients received 20-30 vials and only one patient 
received more than 30 vials. 
 Regarding  time delay in starting ASV , 124 patients received ASV 
within 6  hrs of bite and  59 patients received  between 7-12 hrs and 17 
patient received after 12 hrs of bite. Because most  of the patients 
received  ASV in time, mortality was as less as 5% in our study but still a 
portion of patients who received ASV  after a delay and those who 
received in time outside the institution, which was  inadequate had a 
relatively more mortality and morbidity. 
       Even though complications developed in patients receiving the treatment 
within  6 hours , these complications like renal failure are usually reversible  
and the mortaliry is 1.6% only. For those who received ASV in 6-12 hours 
mortality was 3.3%.but for those who received ASV after12hours had a 
mortality of 21 %. 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY AND CONCLUSIONS 
SUMMARY AND CONCLUSION 
In our study:  
 1 .  Males were commonly affected. Seasonal variation was present 
in snake bite .Incidence and mortality were more during March - 
April. Most of the cases of the snake bite are from rural area.   
2.  The clinical profile of our study is more hematological 
toxicity,62% seek medical advice within  6 hours of bite.Lower 
extremity is the common area of bite. 
3.  Of the identified snakes ,Viper was the commonest and because 
of high incidence of haematological toxicity alone viperidae may 
be common species here. Viper bite was the commonest cause of 
renal failure in snake bite. 
4.  Hypotension, conjunctival haemorrhage,anuria  during 
presentation were associated wth increased mortality. 
5.  Mortality  was less in patients who came within 6 hours and least 
in patient who had received 10 vials of ASV within 6 hours . 
6. Neuroparalysis, hypotension,subconjunctival haemorrhage 
necessitates administration of more than 20 vials. 
 
7. Mortality in our study was 5%. 
8. Commonest cause of death are septicemia, renal failure, and 
coagulation abnormalities. 
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ANNEXURE 
  
ANNEXURE    I 
 
CERTIFICATE OF CONSENT 
 
 
      I have been invited to participate in research on snake bite 
envenomation. I understand that it will involve answering a detailed 
questionnaire, undergoing a thorough physical exam, giving blood and 
urine samples .I have been informed that the risks are minimal and may 
include only slight pain and redness at sight of needle prick. I am aware 
that there may be no benefit to me personally and that I will not be 
compensated monetarily. I have been provided with the name of a 
researcher who can be easily contacted using the number and address I 
was given for that person.. I have had the opportunity to ask questions 
about it and any questions I have asked have been answered to my 
satisfaction. I consent voluntarily to participate as a participant in this 
research and understand that I have the right to withdraw from the 
research at anytime without in anyway affecting my medical care. 
 
 
Name of the participant:      
____________________ 
Signature of the participant:    
 ____________________ 
Date:       
 ____________________ 
         (DD/MM/YY) 
 
 If  illiterate,  a  witness must sign ( if possible, this  person  should  
be  selected  by  the participant  and  must have no connection to the 
research team).  
  
           I  have  witnessed  the accurate reading  of  the consent form to the 
potential  participant, translated  to his/ her  mother tongue ,   and  the 
individual  has  had opportunity to ask questions. I confirm that the 
individual has given the consent freely. 
 
Name of the witness                                       Thumb  print  of  participant 
Signature of the witness;                
                   
Date; 
           
        
 I have  accurately read or witnessed the accurate reading  of  the  
consent form to the  potential  participant, I  confirm that the  individual 
has given the consent freely. 
 
Name  of  the  researcher; 
Signature of  the researcher  with  date; 
  
 
                                                PROFORMA 
(Part I: Details to be filled in at IMCU before transfer to the ward) 
 
Name: ___________________________Age:_______  Sex:_____ IP  
NO:______  
Address 
District:_________________Taluk:_________________Village_______
______    
Occupation: _______________________ Contact telephone 
___________.   
 
Admitting unit:___  Time of bite(am/pm):___ Place   □ In And Around 
House    □ Field                    
 
Type of snake: □ identified □ not identified if identified 
specify;______________________  
Site  of bite  □upper limb         □ lower limb   □trunk    □Head      
First aid given ( □  yes□   no)  if yes  □Tourniquet  □incising wound 
□substances applied on wound □others 
Any alternative medicine given □yes □ no if yes 
specify___________________________________ 
Symptoms and signs 
LOCAL  
SYSTEMIC 
□Fang marks □Diplopia 
□Oozing □Lymph nodes 
□Cellulitis □Ophathalmoplegia 
□Blisters □Others  
□Skin changes 
 
 
FUNDUS Hematologic 
 
Neurologic □Bleeding 
□Ptosis □Hematuria 
 
Clotting time :__________    ASV given   □yes    □ no     No of vials          
_________________       
Reaction to ASV: □NIL, □Mild(pruritus,nausea,vomiting) ,□Severe 
(respdistress, hypotension)  
 
Time delay between bite and ASV:________________________ 
Complications  :  □Shock (sbp <90) □Stroke □Compartment 
syndrome 
□Gangrene  □Respiratory paralysis delayed 
□ Others specify _________________ 
 
Transfusions given      □   Yes            □  No    if yes give details 
below 
Component No of packs 
  
  
  
 
Part II: Details to be filled in the medical ward at discharge 
(kindly go through the details filled above and correct if necessary) 
Duration of hospital stay:  Total_________   IMCU:_______  
Ward:________ 
Investigations 
          Date of  investigaiton 
Investigation     
Hemoglobin     
Total count     
Diff count     
ESR     
Platelets     
Hematocrit     
Blood urea     
Sr creatinine     
Sr Na     
Sr K     
Urine alb     
Urine deposits     
Urine bile 
pigments 
    
Urine sugar     
AST     
ALT     
ALP     
S. Bilirubin     
Prothrombin 
time* 
    
FDP*     
(* if the patient has bleeding tendency) 
Kindly enter the complication developed in the ward in Part I of this 
proforma 
 
ECG  : 
DATE OF   DISCHARGE: 
CONDITION ON DISCHARGE : 
ABBREVIATIONS 
AKI – Acute Kidney Injury 
IMCU – Intensive Medical Care Unit 
UP – Uttar Pradesh 
BP – Blood Pressure 
PR – Pulse Rate 
HR – Haemorrhagin 
DIC – Disseminated Intravascular Coagulation 
MAHA – Micro Angiopathic Hemolytic Anemia 
RVV – Russells’ Viper Venom 
ARF – Acute Renal Failure 
LDH – Lactate De Hydrogenase 
CaCl2 – Calcium Chloride 
CPK – Creatinine Phospho Kinase 
CK – Congested Kidney 
ABG – Arterial Blood Gas 
ASV – Anti Snake Venom 
AV block – Atrio Ventricular Block 
DNA – Deoxy Ribo Nucleic Acid 
WBCT – Whole Blood Clotting Time 
FDP – Fibrin Degradation Product 
ATN – Acute Tubular Necrosis 
MOA  - mechanism of action 
TOS   -  Type of snake 
SOB  -  Site of bite 
POS - pain or swelling 
OFS - oozing from site 
HU - haematuria 
OLIG- oliguria 
SCH - subconjunctival haemorrhage 
MAL -malena 
HE -  hematemsis 
ANU - anuria 
BG    - bleeding gums 
DEL - drooping of eyelid 
R.PAR -respiratory paralysis 
RF  - Renal failure 
CTP - clotting time prolongation 
TBAB- time between bite and ASV administration 
NASV - number of ASV 
ASVO - ASV given outside 
TASV - Total ASV given 
NOD - number of dialysis 
HS -   Hospital stay duration 
OC -  outcome 
  
   
S.No Sex AGE AREA MOA TOS SOB BP PS OFS HU OLIG SCH MAL HE ANU BG DEL R.PAR R F CTP TBAB(hr NASV ASVO BT       TASV NOD HS OC
1 m 19 U sep u LL 130/80 y n n n n n n n n n n n y 3 10 0 N 10 0 3 D
2 m 27 SU sep v LL 90/60 y y y y y n y y y n n y y 18 25 5 Y 30 3 7 E
3 m 17 SU sep v LL 140/90 y y n n n n n n n n n n y 2 10 0 N 10 0 3 D
4 m 37 R sep v LL 130/80 y n n n n n n n n n n n y 3 5 3 N 10 0 3 D
5 m 29 R sep u UL 120/80 n n n n n n n n n n n n y 3 5 2 N 7 0 4 D
6 m 34 R sep u LL 130/80 y Y n Y n n n y n n n y y 4 15 2 N 17 2 6 D
7 F 45 R sep u UL 130/80 n n n n n n n n n n n n y 5 5 0 N 5 0 3 D
8 F 26 R sep v UL 150/90 y y n y n n n n n n n y y 7 15 5 Y 20 0 4 D
9 M 59 U sep k LL 130/80 n n n n n n n n n y n n n 5 10 2 N 12 0 3 D
10 M 39 R sep c LL 120/70 n n n n n n n n n y y n n 5 20 5 Y 25 0 6 D
11 M 14 R sep v LL 110/70 y y y y y y n y y n n y y 5 25 3 Y 28 4 6 E
12 M 56 SU sep v LL 140/90 y n n n n n n n n n n n y 2 15 0 N 15 0 3 D
13 M 27 R sep u LL 110/70 n n n n n n n n n n n n y 5 5 5 N 10 0 3 D
14 M 17 R sep u LL 150/90 y n n n n n n n n n n n n 6 10 0 N 10 0 4 D
15 F 25 R sep k LL 140/80 y n n n n n n n n y y n n 10 25 3 N 28 0 7 D
16 m 21 R sep v LL 130/80 y y n y n n n y y n n y y 9 20 5 N 25 2 13 D
17 F 28 R sep u LL 120/70 y y n n n n n n n n n n n 5 6 4 N 10 0 3 D
18 M 32 U sep u LL 110/70 y n n n n n n n n n n n y 2 5 0 N 5 0 2 D
19 M 59 R sep u LL 110/70 y y n y n n n y n n n y y 12 20 3 N 23 2 13 D
20 M 27 R sep u LL 120/80 n n n n n n n n  n y n n n 9 10 8 N 18 0 4 D
21 M 35 SU oct v UL 120/70 y n n n n y n n n n n n y 8 8 0 N 8 0 3 D
22 M 52 R oct v LL 160/90 y n n n n n n n n n n n y 4 7 2  N 9 0 3 D
23 M 29 R oct u LL 110/70 n n n n n n n n n n n n y 4 7 0 N 7 0 2 D
24 M 34 R oct c LL 110/70 n n n n n n n n n y n n n 7 15 0 N 15 0 4 D
25 M 36 R oct u TR 120/80 y y y y n y n y y n n y y 12 20 3 Y 23 2 12 D
26 F 21 R oct v LL 130/90 n n n n n n n n n n n n y 3 7 0 N 7 0 3 D
27 F 27 U oct v LL 140/90 y n n n n n n n n n n n y 5 8 1 N 9 0 3 D
28 F 35 R oct v LL 130/80 y y n n n n n n n n n n y 3 10 0 N 10 0 3 D
29 M 41 U oct u LL 90/760 n n n n n n n n n n n n y 1 5 0 N 5 0 2 D
30 M 27 R oct u LL 100/70 y y n n n n n n n n n n y 3 8 2 N 10 0 3 D
31 M 55 R oct u LL 120/80 n n n n n n n n n n n n y 4 5 0 N 5 0 2 D
32 M 21 R oct u LL 110/70 y n n y n n n y y n n y y 2 20 0 Y 20 1 5 D
33 M 42 R oct v LL 120/80 y y n y n y n n n n n n y 1 15 0 N 15 0 4 D
34 M 38 U oct k LL 130/80 n n n n n n n n n y y n y 2 20 0 Y 20 0 5 D
35 F 53 R oct v UL 140/90 y y y y n n n y n n n y y 3 25 0 N 25 1 7 D
36 M 30 R oct v UL 140/80 y n n n n n n n n n n n n 4 6 5 N 11 0 2 D
37 M 15 R oct v LL 140/90 y n n n n n n n n n n n y 7 5 0 N 5 0 3 D
38 M 53 R oct v LL 130/70 y n n n n n n n n n n n y 5 6 0 N 6 0 3 D
39 F 31 SU oct u LL 100/70 n n n n n n n n n n n n y 4 7 2 N 8 0 3 D
40 M 29 R oct u LL 130//80 y y n n n n n n n n n n y 1 5 0 N 5 0 3 D
41 M 39 U oct u LL 100/70 y y n y n n n n n n n n y 3 10 0 N 10 0 3 D
42 M 44 R oct u LL 70/50 y n n n n n n n n n n n y 4 10 0 N 10 0 3 D
43 M 16 R oct u LL 160//90 y n n n n n n n n n n n y 3 7 3 N 10 0 4 D
44 M 32 R oct v LL 130/80 y y n n y n n y y n n n y 11 20 3 N 23 2 16 D
45 F 18 SU oct v LL 140/90 n n n n n n n n n n n n y 1 5 0 N 5 0 3 D
46 M 59 R oct k LL 130/80 n n n n n n n n n y n n n 3 15 0 N 15 0 4 D
47 F 21 U nov c UL 110/70 y n n n n n n n n y y n n 11 18 2 N 20 0 6 D
48 F 28 R nov v UL 120/80 y n n y n n n n n n n n y 3 6 0 N 6 0 3 D
49 F 44 SU nov v UL 110/70 y y n y n n n n n n n n y 7 8 5 N 13 0 4 D
50 F 17 R nov v LL 100/70 y n n n n n n n n n n n n 5 5 0 N 5 0 2 D
Master Chart 
51 F 34 R nov c UL 110/70 y n n n n n n n n y n n n 7 10 8 N 18 0 4 D
52 F 37 R nov c UL 90/60 y n n n n n n n n y y n n 16 20 10 Y 30 0 5 E
53 M 21 R nov c UL 110/70 y n n n n n n n n y n n n 5 15 0 N 15 0 5 D
54 F 49 R nov k UL 100/70 y n n n n n n n n y y n n 4 18 8 N 26 0 6 D
55 F 19 U nov v UL 130/80 y n n n n n n n n n n n y 6 5 0 N 5 0 3 D
56 F 39 R nov u UL 140/90 y n n n n n n n n n n n y 3 12 0 N 12 0 4 D
57 M 29 R nov u UL 110/70 y y y y y y n y n n n n y 24 25 0 N 25 3 5 E
58 F 43 R nov u LL 160/90 y n y n n n n n n n n n y 5 10 5 N 15 0 4 D
59 M 39 R nov u LL 140/80 y n n n n n n n n n n n y 14 10 6 N 16 0 3 D
60 M 13 U nov u LL 130/80 y n n n n n n n n n n n y 1 10 0 N 10 0 2 D
61 M 30 R nov k LL 120/70 n n n  n n n n n n y n n y 4 15 0 N 15 0 4 D
62 M 56 R nov c LL 120/80 y n n n n n n n n y n n n 9 15 7 N 22 0 4 D
63 M 28 R nov v LL 130/70 y y y y n n n n n n n n y 10 15 8 Y 23 0 5 D
64 F 52 R nov v LL 130/80 y n n n n n n n n n n n y 4 12 0 N 12 0 4 D
65 M 29 R dec v UL 130/90 y y n n n n n n n n n n y 3 8 0 N 8 0 3 D
66 M 18 R dec c UL 130/80 n n n n n n n n n y n n n 5 15 0 N 15 0 5 D
67 M 45 R dec u LL 130/70 y n n y n n n n n n n n y 10 10 0 N 10 0 4 D
68 F 27 R dec u UL 130/80 y n n n n n n n n y y n n 16 15 5 N 20 0 6 D
69 M 19 R dec v LL 110/70 y y n y y y n y y n n y y 8 20 4 N 24 3 11 D
70 M 30 R dec k UL 110/70 n n n n n n n n n y y n n 7 18 7 Y 25 0 6 D
71 F 38 R dec c LL 120/80 y n n n n n n n n y n n n 9 10 8 N 18 0 6 D
72 M 27 R dec c LL 120/80 n n n n n n n n n y n n n 6 10 5 N 15 0 5 D
73 M 15 R dec v UL 140/80 y y n y n n n n n n n n n 1 10 0 N 10 0 3 D
74 M 23 R dec u UL 120/70 y n n n n n n n n n n n y 8 9 5  N 14 0 3 D
75 M 21 R dec u LL 120/80 y n n y n n n n n n n n y 7 8 5 N 13 0 4 D
76 M 28 R dec u LL 130/60 n n n n n n n n n n n n y 4 10 0 N 10 0 3 D
77 F 31 R dec v LL 80/60 y y y y n y y y y n n y y 12 25 5 Y 30 2 7 E
78 F 16 R dec u LL 120/80 y n n y n n n n n n n n y 2 10 0 N 10 0 3 D
79 M 42 R dec u UL 150/90 y n n n n n n n n n n n y 5 10 0 N 10 0 6 D
80 M 39 SU dec v UL 130/80 y n y y y n n y n n n y n 12 20 8 N 28 1 8 D
81 M 25 R dec k UL 140/90 y n n n n n n n n y n n n 2 15 0 Y 15 0 5 D
82 M 21 R dec u LL 120/80 n n n n n n n n n n n n y 4 10 0 N 10 0 3 D
83 M 37 R dec v LL 130/80 y y n y n n n n n n n n y 5 18 0 N 18 0 4 D
84 M 16 R dec u LL 140/90 n n n n n n n  n n n n n y 1 5 0 N 5 0 3 D
85 M 44 R dec v LL 130/80 n n n n n n n n n n n n y 5 10 0 N 10 0 3 D
86 M 14 SU dec u LL 140/90 y n n n n n n n n y n n n 13 15 10 N 25 0 5 D
87 M 28 R dec c LL 120/80 y n n n n n n n n y y n n 10 20 4 N 24 0 6 D
88 F 21 R dec u LL 120/80 y n n n n n n n n n n n y 2 8 0 N 8 0 3 D
89 F 24 R jan v UL 110/70 y y n y n n n y n n y n y 8 18 5 Y 23 0 7 D
90 M 57 R jan v UL 90/70 y y y y y y n y n n n y y 14 20 3 Y 23 2 9 E
91 F 32 R jan v LL 100/60 y n n n n n n n n n n y y 8 20 0 N 20 0 5 D
92 M 63 R jan u LL 120/80 y n n n n n n n n n n n y 3 10 0 N 10 0 3 D
93 M 19 R jan u UL 120/70 y y n y n n n n n n n n y 8 12 0 N 12 0 4 D
94 M 19 R jan u LL 130/80 y n n n n n n n n n n n y 2 8 0 N 8 0 3 D
95 M 30 SU jan u LL 140/90 y n n n n n n n n n n n y 5 10 0 N 10 0 3 D
96 M 43 R jan u UL 120/80 y y n n n n n n n n n n y 2 8 0 N 8 0 4 D
97 F 29 R jan c LL 110/70 y n n n n n n n n y n n n 5 15 7 N 22 0 5 D
98 F 44 R jan v LL 110/80 n n n n n n n n n n n n y 2 10 0 N 10 0 4 D
99 M 32 R jan v LL 130/70 y n n n n n n n n n n n y 3 8 0 N 8 0 3 D
100 M 26 R jan v UL 140/90 y y y y n n n y n n n y y 9 20 4 N 24 2 8 D
  
 101  M 38 SU jan k LL 120/80 y n n n n n n n y n n n n 2 18 0 N 18 0 4 D
102 M 21 R jan u UL 130/80 n n n n n n n n n n n n y 4 8 0 N 8 0 3 D
103 M 22 R jan u LL 130/70 n n n n n n n n n n n n y 8 10 0 N 10 0 2 D
104 M 34 R jan u LL 120/80 n n n n n n n n n y n n n 2 15 0 N 15 0 4 D
105 M 18 R jan v UL 160/90 y y n y y n n y n n n y y 3 25 0 N 25 1 7 D
106 M 29 R jan v LL 110/70 y n n n n y n n n n n n y 6 10 6 N 16 0 4 D
107 M 19 SU jan u LL 120/80 y n n y n n n n n n n n y 10 8 6 Y 14 0 5 D
108 F 28 R jan u UL 110/70 y n n n n n n n n y n n n 4 16 0 N 16 0 4 D
109 F 27 R jan c LL 110/70 y n n n n n n n n y y n n 9 18 5 N 23 0 8 D
110 F 39 R jan u LL 120/80 y n n y n n n n n n n n y 5 10 0 N 10 0 3 D
111 F 32 R jan v UL 120/70 n n n n n n n n n n n n y 3 12 0 N 12 0 2 D
112 M 25 R jan v UL 130/80 y y n y n n y n n n n n y 7 8 6 N 14 0 3 D
113 M 30 R jan u LL 140/70 n n n y n n n n n n n n y 5 10 0 N 10 0 2 D
114 M 58 SU feb v LL 140/90 y y y y y y n n y n n y y 14 16 8 Y 24 1 6 D
115 F 28 R feb k LL 130/80 y n n n n n n n n y n n y 8 15 5 N 20 0 5 D
116 F 35 R feb v LL 120/60 y y n n n n n n n n n n y 9 12 0 N 12 0 4 D
117 F 17 R feb c UL 110/70 y n n n n n n n n y n n n 7 15 0 N 15 0 5 D
118 M 51 R feb u LL 140/90 y n n y n n n n n n n n y 2 8 0 N 8 0 3 D
119 M 49 R feb u UL 130/90 y n n n n n n n n n n n y 7 12 3 N 15 0 4 D
120 M 55 R feb v LL 140/90 y y n y n n n y n n n y y 9 13 4 N 17 1 5 D
121 M 34 R feb v UL 120/80 y n n y n n n y n n n n y 4 10 0 N 10 0 3 D
122 M 27 R feb u LL 120/80 n n n n n n n n n y n n y 3 15 0 N 15 0 4 D
123 M 16 SU feb v LL 110/70 y y y y y n n n n n n y y 4 12 6 N 18 0 5 D
124 M 28 R feb v UL 130/80 y n n n n y n y y n n n y 3 15 0 N 15 0 4 D
125 M 41 R feb u LL 140/90 n n n n n n n n n n n n y 4 8 0 N 8 0 3 D
126 M 29 R feb v LL 140/90 y n n y n n n n n n n n y 12 8 7 N 15 0 4 D
127 M 18 R feb k LL 130/80 n n n n n n n n n n n n y 6 7 0 N 7 0 2 D
128 M 17 R feb c LL 90/70 y n n n n n n n y y y n n 24 25 6 N 31 0 3 E
129 M 34 R feb u LL 110/70 n n n n n n n n n n n n y 1 8 0 N 8 0 2 D
130 F 24 R feb v UL 120/80 y y y y n n n y n n n y y 8 17 6 Y 23 1 7 D
131 F 13 R feb v LL 140/90 y y n y n n n y n n n y y 16 20 5 Y 25 1 6 D
132 F 46 R mar u UL 140/80 y y n y n n n n n n n n y 5 18 0 N 18 0 4 D
133 M 26 R mar v UL 120/80 y n n n n n n n n n n n y 3 8 0 N 8 0 3 D
134 F 14 R mar u LL 110/70 y n n y n n n n n n n n y 5 12 0 N 12 0 3 D
135 M 28 SU mar u LL 70/50 y y y y n y n y n n n y y 12 22 3 Y 25 3 8 D
136 M 26 R mar k LL 110/70 y n n y n n n n n y n n y 6 20 0 N 20 0 5 D
137 M 23 R mar k LL 120/80 n n n n n n n n n y n n n 1 15 0 N 15 0 4 D
138 M 58 R mar v UL 130/80 n n n n n n n n n n n n y 2 6 0 N 6 0 3 D
139 F 21 R mar v LL 120/80 y n y n n n n n n n n n y 3 10 0 N 0 0 2 D
140 M 19 R mar u F 110/70 y n n y n n n n n n n n y 8 8 5 N 13 0 3 D
141 M 58 R mar u UL 130/80 n n n n n n n n n n n n y 6 6 0 N 6 0 3 D
142 M 21 R mar c UL 110/70 y n n n n n n n n y n n n 4 15 0 N 15 0 4 D
143 M 15 R mar u UL 120/80 y y y y n n y y n n n y y 9 18 4 N 22 1 5 D
144 M 47 R mar u TR 130/80 n n n n n n n n n n n n y 3 8 0 N 8 0 4 D
145 F 34 R mar v UL 110/70 y n y y n n n n n n n y y 24 20 5 N 25 2 6 D
146 F 13 SU mar v UL 120/80 y y y y n n n n n n n n y 3 15 0 N 15 0 4 D
147 F 29 R mar k UL 11O/70 n n n n n n n n n y n n n 5 14 0 N 14 0 5 D
148 M 53 R mar u LL 70/50 y y y y y y n y y n n y y 16 22 5 N 27 2 8 E
149 M 18 R mar u TR 100/70 n n n n n n n n n n n n y 2 8 0 N 8 0 3 D
150 M 23 R mar u UL 110/70 y n n y n n n n n n n n y 5 12 0 N 12 0 3 D
151 M 45 R mar v LL 110/80 y y y y n n n n n n n n y 9 10 7 N 17 0 4 D
152 M 34 SU mar c LL 100/70 n n n y n n n n y n n n n 6 18 0 N 18 0 5 D
153 M 63 R mar v LL 130/80 y n n n  n n n n n n n n y 4 7 0 N 7 0 3 D
154 M 25 R mar v LL 120/70 y y y y n y n n n n n y y 2 15 0 N 15 0 4 D
155 M 19 SU mar v LL 110/70 y y n n n n n n n n n n y 3 10 0 N 10 0 3 D
156 M 35 R mar v LL 120/80 y n y y n n n n y n n y y 9 16 7 Y 23 0 5 D
157 F 28 R mar u UL 60/40 y y y y n y y y y n n y y 7 15 6 N 21 1 7 D
158 F 16 SU mar u UL 100/70 n n n n n n n n n n n n y 2 7 0 N 7 0 3 D
159 M 30 R mar c UL 110/70 y n n y n n n n n y n n n 5 16 0 N 16 0 5 D
160 M 23 R mar v UL 100/70 y y n y n n n n n n n n y 8 12 5 N 17 0 4 D
161 M 29 R mar v LL 110/70 y y y y n y n n n n n y n 7 15 0 N 15 0 4 D
162 M 45 SU mar u LL 110/80 n n n n n n n n n n n n y 1 5 0 N 5 0 3 D
163 M 29 R apr u LL 120/80 y n n n n n n n n n n n y 4 8 0 N 8 0 3 D
164 M 65 R apr u LL 160/90 y y y y n n n n n n n y y 9 18 2 N 20 0 5 D
165 M 27 SU apr u LL 110/70 n n n n n n n n n n n n y 5 5 0 N 5 0 5 D
166 F 37 R apr u UL 70/50 y n n n n n n n n y n n y 3 6 0 N 6 0 5 D
167 F 19 R apr v LL 100/70 y y y n n n n n n n n n y 9 12 4 Y 16 0 4 D
168 M 54 SU apr v LL 110/80 y n n y n n n n n n n n y 4 15 0 N 15 0 4 D
169 M 67 R apr v UL 150/90 y n n y n n n n n n n n y 8 10 0 N 10 0 4 D
170 M 19 R apr c UL 110/70 y n n y n n n n n y y n y 12 18 5 Y 23 0 7 D
171 F 39 SU apr u LL 130/80 y n y y n n y n n n n n y 10 15 8 N 23 0 6 D
172 M 23 R apr v LL 140/90 y y y y n y y y n n n y y 10 20 4 N 24 3 9 E
173 M 65 R apr c LL 150/90 n n n n n n n n n y n n n 5 15 0 N 15 0 4 D
174 F 62 SU apr u LL 150/90 y y y y y n y y y n n y y 6 26 0 Y 26 1 8 D
175 M 26 R apr v LL 110/70 y n n n n n n n n n n n y 8 15 0 N 15 0 3 D
176 M 18 R apr u UL 100/70 y y n y n n n n n n n n y 5 12 0 N 12 0 3 D
177 M 21 SU apr u LL 100/60 y n n n n n n n n n n n y 2 8 0 N 8 0 2 D
178 M 25 R apr u LL 120/80 y n n n n n n n n y n n n 6 7 0 N 15 0 2 D
179 M 30 SU apr v UL 60/40 y y y n n n n n n n n n y 8 9 5 N 14 0 5 D
180 M 17 R apr k LL 110/90 y n n n n n n n n y n n y 3 15 0 N 15 0 6 D
181 M 26 R apr u LL 120/80 y y n y n n n n y n n n y 9 15 4 N 19 0 4 D
182 F 21 R apr v UL 110/70 y n n n n n n n n n n n y 3 7 0 N 7 0 3 D
183 M 42 R apr u LL 130/80 n n n n n n n n n n n n Y 4 5 0 N 5 0 3 D
184 F 25 R apr v LL 140/90 y y n y n n n n n n n n y 12 12 5 N 17 0 6 D
185 M 63 R apr c UL 110/70 y n n n n n n n n y n n Y 6 15 0 N 15 0 4 D
186  M 29 R apr u LL 120/80 y y n y n n n n n n n y y 5 18 0 N 18 0 4 D
187 M 47 R apr u LL 90/60 y y y y y y y y n n n y y 20 26 10 N 36 3 6 E
188 M 24 R apr v UL 100/60 y n n y n n n n n n n n y 5 10 0 N 10 0 3 D
189 F 39 R apr u LL 90/60 y y y y n y n y n n n y y 8 25 0 N 25 1 7 D
190 M 16 R apr u UL 110/70 y n n n n n n n n n n n y 4 15 0 N 15 0 5 D
191 M 29 R apr v LL 120/80 y y n y n n n n n n n n y 8 16 5 N 21 0 4 D
192 M 28 R apr v LL 130/80 y n n y n n n n n n n n y 3 10 0 N 10 0 5 D
193 F 43 R apr u UL 140/90 y n n n n n n n n n n n y 5 12 0 N 12 0 3 D
194 M 31 R apr u UL 90/60 y y y n n y y y n n n y y 14 20 10 Y 30 1 8 D
195 M 26 R apr u UL 100/70 n n n n n n n n n n n n y 3 10 0 N 10 0 3 D
196 M 21 R apr u UL 110/70 y n n n n n n n n n n n y 4 15 0 N 15 0 4 D
197 M 13 R apr c LL 110/70 y n n n n n n n n y n n y 9 18 7 N 25 0 6 D
198 M 19 R apr u TR 120/80 y y n y n n n n n y n n y 3 10 0 N 10 0 10 D
199 M 38 R apr u LL 110/70 n n n n n n n n n n n n y 4 8 0 N 8 0 3 D
200 F 37 R apr u LL 110/70 n n n n n n n n n n n n Y 3 7 0 N 7 0 3 D
 
